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Abstract
Polycomb repressive complex-2 (PRC2) is a group of proteins that
play an important role during development and in cell differentia-
tion. PRC2 is a histone-modifying complex that catalyses methyla-
tion of lysine 27 of histone H3 (H3K27me3) at differentiation genes
leading to their transcriptional repression. JARID2 is a co-factor of
PRC2 and is important for targeting PRC2 to chromatin. Here, we
show that, unlike in embryonic stem cells, in lineage-committed
human cells, including human epidermal keratinocytes, JARID2
predominantly exists as a novel low molecular weight form, which
lacks the N-terminal PRC2-interacting domain (DN-JARID2). We
show that DN-JARID2 is a cleaved product of full-length JARID2
spanning the C-terminal conserved jumonji domains. JARID2 knock-
out in keratinocytes results in up-regulation of cell cycle genes and
repression of many epidermal differentiation genes. Surprisingly,
repression of epidermal differentiation genes in JARID2-null kerati-
nocytes can be rescued by expression of DN-JARID2 suggesting
that, in contrast to PRC2, DN-JARID2 promotes activation of dif-
ferentiation genes. We propose that a switch from expression of
full-length JARID2 to DN-JARID2 is important for the up-regulation
differentiation genes.
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Introduction
Polycomb group (PcG) proteins are very important transcriptional
repressors and play a crucial role in regulating gene expression
during development (Margueron & Reinberg, 2011; Holoch &
Margueron, 2017). They function by catalysing histone modifi-
cations that result in repressive chromatin and down-regulation of
neighbouring genes. Polycomb group proteins form two major
complexes, polycomb repressive complex-1 (PRC1) and polycomb
repressive complex-2 (PRC2). PRC2 functions by catalysing
trimethylation of histone H3 at lysine 27 (H3K27me3; Simon &
Kingston, 2013). Polycomb repressive complex-2 consists of four
core proteins, SUZ12, EED, RbAp46/48 and the catalytic subunit
EZH2. At the molecular level, how PRC2 is recruited to its sites of
action is not yet completely clear. Recent proteomic studies have
revealed that PRC2 transiently associates with many proteins such
as MTF2, EPOP, AEBP2 and JARID2 that typically interact with
PRC2 in a mutually exclusive fashion resulting in different
subclasses of PRC2 (Kim et al, 2009; Peng et al, 2009; Shen et al,
2009; Landeira et al, 2010; Li et al, 2010; Pasini et al, 2010; Walker
et al, 2010; Casanova et al, 2011; Landeira & Fisher, 2011; Beringer
et al, 2016; Grijzenhout et al, 2016; Liefke et al, 2016; Holoch &
Margueron, 2017). Although the molecular roles of many of these
interacting proteins are not well understood, many of them can
modulate enzymatic activity or recruitment of PRC2 to chromatin
(Holoch & Margueron, 2017).
JARID2 is required for recruitment of PRC2 to chromatin in
embryonic stem cells (Peng et al, 2009; Shen et al, 2009; Landeira
et al, 2010; Li et al, 2010; Pasini et al, 2010; Landeira & Fisher,
2011; Holoch & Margueron, 2017). Multiple studies in mouse and
human show that N-terminal region of JARID2 (Fig 1A) is required
for PRC2 recruitment and modulation of PRC2 activity (Cooper, Son
et al, 2013; Kaneko et al, 2014a; da Rocha et al, 2014; Sanulli et al,
2015; Grijzenhout et al, 2016). The N-terminal region consists of a
nucleosomal binding domain and a RNA binding domain that
together modulate PRC2 binding to genomic DNA (Son et al, 2013;
Kaneko et al, 2014a; da Rocha et al, 2014). In addition, recently it
has been shown that this region of JARID2 is needed for recruitment
of PRC2- to PRC1-modified nucleosomes (Cooper et al, 2016). It is
clear from multiple studies that removal of JARID2 results in
reduced occupancy of PRC2 on chromatin (Peng et al, 2009; Shen
et al, 2009; Landeira et al, 2010; Li et al, 2010; Pasini et al, 2010;
Landeira & Fisher, 2011). But surprisingly, JARID2 removal does
not result in significant and consistent changes in H3K27me3 levels
(Landeira & Fisher, 2011). Although in some studies JARID2 deple-
tion in ES cells is observed to decrease H3K27me3 levels (Landeira
et al, 2010; Pasini et al, 2010), other studies have reported either no
change (Peng et al, 2009) or increased levels of H3K27me3 upon
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JARID2 removal (Peng et al, 2009; Shen et al, 2009). Further adding
to this lack of clarity on the role of JARID2 in modulation of PRC2
activity, in in vitro studies JARID2 appears to inhibit (Peng et al,
2009; Shen et al, 2009) as well as activate (Li et al, 2010) the
methyltransferase activity of EZH2. It has been suggested that
JARID2’s N-terminal domain interacts with RNAs as well as nucleo-
somes (Son et al, 2013; Kaneko et al, 2014b) and its post-transla-
tional modifications determine its effect on PRC2 activity (Sanulli
et al, 2015). A recent study has also shown that, in mouse ES cells,
JARID2 can modulate PRC2 activity through its interaction with
another histone methylase, setDB1 (Fei et al, 2015). JARID2-setDB1
interaction has also been identified in lineage-committed cells
including lymphocytes (Macian et al, 2002; Pereira et al, 2014) and
cardiomyocytes (Mysliwiec et al, 2011) where JARID2 is shown to
modulate other histone modifications such as H3K9me3.
The C-terminal of JARID2 has three conserved domains (jmjN,
ARID, jmjC) that are characteristic of the jumonji family of histone
modifiers (Fig 1A), which catalyse demethylation of histones. The
C-terminal ARID domain of JARID2 is required for DNA binding. In
addition, JARID2 C-terminus also has a zinc finger domain, which is
needed for its interaction with SUZ12, another component of PRC2
(Peng et al, 2009). The jmjC domain is required for demethylase
activity in other jumonji family members. However, two amino acid
changes in JARID2’s demethylase domain are thought to render it
inactive (Klose et al, 2006; Landeira & Fisher, 2011).
Despite its lack of demethylase activity, JARID2 acts as an impor-
tant regulator of gene expression in embryonic stem (ES) cells
where it is needed for cell signalling networks necessary for main-
taining the pluripotent state (Sun et al, 2008; Assou et al, 2009;
Yaqubi et al, 2015; Sahu & Mallick, 2016). Consistent with this, a
recent report suggests that forced expression of JARID2 alongside
PRDM14, ESRRB and SALL4A can efficiently induce pluripotency in
fibroblasts (Iseki et al, 2016). More importantly, a number of publi-
cations have shown that JARID2-deleted ES cells either cannot dif-
ferentiate or are delayed in differentiation (Peng et al, 2009; Shen
et al, 2009; Landeira et al, 2015; Sanulli et al, 2015). These findings
reflect a crucial role of JARID2 in early embryonic development at
the onset of ES cell differentiation. Indeed, JARID2 is indispensable
for normal embryonic development and its deficiency leads to defor-
mation of several tissues in mice as well as in humans (Jung et al,
2005; Takeuchi et al, 2006; Landeira & Fisher, 2011). Embryos with
a complete loss of JARID2 either do not survive or die soon after
the birth (Jung et al, 2005; Takeuchi et al, 2006; Shen et al, 2009;
Landeira et al, 2010).
Although the importance of JARID2 in ES cells has been estab-
lished, its role in lineage-committed cells has not been well studied,
mainly because of its much lower level of expression or perceived
absence (Zhang et al, 2011; Son et al, 2013). In this study, we show
that, in many lineage-committed cells including human epidermal
keratinocytes, JARID2 predominantly exists as a low molecular
weight (LMW) form. In the LMW form, the N-terminal region is
cleaved from full-length JARID2 resulting in a stable C-terminal frag-
ment (DN-JARID2). This form of JARID2 lacks N-terminal nucleo-
somal and RNA binding domains (Son et al, 2013; Kaneko et al,
2014a), implying a substantial effect on JARID2 functionality and its
interactions with PRC2 complex. Consistent with this, a recent study
showed that C-terminal region of JARID2 cannot restore H3K27me3
marks (Cooper et al, 2016). We show that the level of DN-JARID2
increases as differentiation of keratinocytes progresses. We find that
JARID2 knockout results in impaired differentiation of keratinocytes
and this effect is reversed by expression of DN-JARID2, indicating
that this form of JARID2 is needed for activation of polycomb target
genes during differentiation.
Results
A low molecular weight form of JARID2 exists in lineage-
committed cells
JARID2 has been extensively studied in embryonic stem (ES) cells
where it is reported as a 140 kDa protein (Fig 1B). It is thought that
JARID2 is not expressed or is expressed at very low levels in
lineage-committed cells (Zhang et al, 2011; Son et al, 2013). There-
fore, we investigated JARID2 mRNA as well as protein expression in
multiple types of lineage-committed human cells (Fig 1B and C). In
most cell types, JARID2 mRNA is present at detectable but lower
levels than in the ES cells (Fig 1C). Surprisingly, when we investi-
gated protein levels in lineage-committed cells (Fig 1B), we detected
another band at around ~80 kDa that has not been reported previ-
ously. We observed that in the majority of cell types we studied, this
band is much more dominant than the 140 kDa band corresponding
to the canonical full-length JARID2 isoform-1 (Fig 1B). To verify
that this low molecular weight form is encoded by JARID2 and is
not a non-specific band cross-reacting with our antibody, we trans-
fected keratinocytes (HaCaT cells), HEK293T and K562 cells
(Figs 1D and EV1A and B) with different JARID2 siRNAs designed
to target the 50 (exon 3) and 30-ends (exon 15) of JARID2 mRNA
(Appendix Table S1). Transfection of both siRNAs resulted in disap-
pearance of the ~80kDa band along with the canonical 140 kDa
band (Figs 1D and EV1A and B). The siRNA-mediated knockdown
and Western blot with an alternative JARID2 antibody (Fig EV1B)
confirmed that this is a low molecular weight (LMW) form of
JARID2. To rule out the possibility that this band is a degradation
product of JARID2, we also extracted protein in the presence of
increasing amount of protease inhibitor and observed no difference
in the levels of the LMW form (Fig EV1C).
LMW JARID2 is not a transcriptional isoform
Next, we sought to understand whether the LMW form is translated
from a distinct transcript of JARID2. According to latest ENSEMBL
annotations of human genes, three different mRNA isoforms of
JARID2 have been predicted (Fig 2A; Rosenbloom et al, 2015).
According to size predictions, the three isoforms would produce
proteins of sizes 140, 120 and 106 kDa, much larger than ~80 kDa
indicating that this LMW form might not correspond to one of the
annotated isoforms of JARID2. In addition, the mRNA for isoform-3
does not express exon 15, which is targeted by one of the siRNAs
used in our knockdown experiment (Figs 1D and 2A), indicating
that the ~80 kDa form is not a product of isoform-3. To test whether
it might be a product of a mRNA variant transcribed from an inter-
nal promoter that is not yet part of current annotations, we analysed
a large collection of CAGE (cap analysis gene expression) tag data
that is available through the ENCODE database (Rosenbloom et al,
2013). In CAGE analysis, short fragments from 50 ends of capped
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Figure 1. JARID2 exists as a LMW form (~80 kDa) in many cell types.
A A schematic diagram showing functional domains of JARID2: UIM, ubiquitin interaction motif; transcription repressive domain consisting of sub-domains 1-3; JmjN,
JumonjiN; ARID, AT-rich DNA binding domain; GSGFP which is a SUZ12 binding domain; JmjC, JumonjiC; and ZF, zinc finger domain. Domains 1-3 constitute PRC2-
associated domains. Domain 1 is required for PRC2 stimulation, domain 2 is needed for binding to EZH2, and domain 3 is needed for nucleosomal binding. The RNA
binding domain has been indicated with dashed box.
B Immunoblot of whole-cell lysates from multiple human lineage-committed cell lines using a C-terminal anti-JARID2 antibody. The size of canonical form is 140kDa,
but an additional strong band was detected at around ~80 kDa. The blot is divided according to cell types, which are indicated in the figure.
C qPCR measurements of JARID2 mRNA levels in different cell lines. The RNA levels were measured relative to 18S rRNA. Means and SEs are calculated over at least two
independent experiments and three technical replicates. The data are represented as mean  SE.
D Immunoblot showing that the ~80 kDa band disappears upon treatment of HEK293T and HaCaT cells with siRNAs against exon 3 and exon 15 of JARID2 RNA. Non-
silencing control (NSC) was used as a transfection control. Densitometric measurements corresponding to this experiment are shown in Fig EV1A.
Source data are available online for this figure.
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RNAs are sequenced and mapped back to the genome to find tran-
scription start sites. CAGE tag data clearly indicate that in most of
the cell types we tested (Fig 1B), JARID2 is predominantly tran-
scribed from single transcription start site matching that of JARID2
isoform-1 (Fig 2B). We also designed primers to specifically amplify
each isoform of JARID2 (Appendix Table S2) and carried out qPCR
analysis to detect levels of the three different isoforms. Our qPCR
measurements further confirmed that isoform-1 is the predominant
isoform in these cells (Fig 2C). To rule out the possibility that the
~80 kDA band is a product of an mRNA with same transcription
start site as isoform-1, but with a different splicing pattern, we
amplified JARID2 mRNA using RT–PCR with primers in exon 3 and
exon 15 (Appendix Table S3) which, according to our knockdown
experiments, are part of mRNA that produces this low molecular
weight isoform (Fig 1D). Using these primers, only one product was
amplified and its size as well as sequence confirmed that it
contained all the exons between exon 3 and exon 15 (Fig 2D, see
Appendix). In addition, RT–PCR using primers in the first and the
last exon also amplified only one product of the expected size
(Fig 2D). This confirmed that the LMW form of JARID2 is a product
of mRNA with a complete set of exons as in the case of full-length
mRNA of isoform-1. This suggested that LMW JARID2 is either a
cleaved protein product of full-length JARID2 or is translated from
an internal site that is distinct from the isoform-1 translation site.
LMW JARID2 is a cleaved product of isoform-1
To check whether JARID2 mRNA is translated from two distinct
translation start sites, one corresponding to the reported 140 kDa
product and other corresponding to the ~80 kDa low molecular
weight form, we analysed published ribosome profiling data (Michel
et al, 2015). We could only identify a single ribosome initiation site,
which corresponded to the 140 kDa product (Fig 2E). Taking into
consideration the above observations and the fact that we used a
JARID2 antibody that recognises the C-terminal region of JARID2,
we can predict that a ~80 kDa protein can be produced from transla-
tional start site which is far downstream of translational start site
of isoform-1. However, if LMW JARID2 is a cleaved product of
full-length JARID2, rather than a distinct isoform translated from an
internal start site, mutating the translation start site of JARID2
isoform-1 should also knockdown LMW JARID2. To test this, we
knocked out isoform-1 by CRISPR/Cas9-mediated targeting of its
translation start site (Fig EV2A and B). In knockout (KO) cells,
where we targeted the translation start site of isoform-1, we detected
the same level of mRNA as wild type (Fig EV2C). However, the
LMW JARID2 protein band disappeared (Figs 2F and EV2D). This
supports the hypothesis that the 80 kDa LMW form and JARID2
isoform-1 have identical translation start sites and that the LMW
form is a cleavage product of JARID2 isoform-1.
To further verify that the LMW form is indeed a cleavage product
of JARID2 isoform-1, we transfected HaCaT cells with N-terminally
flag-tagged ORF of full-length JARID2 (FL-JARID2) isoform-1
expressing plasmid vector. If LMW JARID2 is truly derived from
full-length JARID2, we predicted that exogenous expression of full-
length JARID2 would also result in an increase in the levels of the
LMW form. Consistent with this hypothesis, we observed that LMW
levels increased 2- to 3-fold upon exogenous expression of full-
length JARID2 (Figs 2G and EV2E and F). However, in a blot with
anti-Flag antibody, which should detect the N-terminal tag on
JARID2, we could not detect the full-length JARID2, 80 kDa band or
any other low molecular weight product (Fig EV2G), indicating that
the N-terminal portion of JARID2 is missing in these cells. To further
confirm this, we carried out mass spectrometry identification of the
LMW band. In this experiment, we detected peptides spanning only
the C-terminal of JARID2 (Figs 2H and EV3). All these observations
strongly support the hypothesis that the LMW form is a cleaved
product of full-length JARID2 isoform-1 and is missing the N-term-
inal portion. Accordingly, we designated the LMW form DN-JARID2.
To confirm the size of DN-JARID2 and to estimate the cleavage posi-
tion, we prepared plasmid constructs expressing different length C-
terminal fragments of JARID2 (Appendix Fig S1A) and checked if
their predicted protein products (103, 88 and 79 kDa) run at a simi-
lar size to DN-JARID2 (Appendix Fig S1B). We found that the frag-
ment spanning 554-1,246 amino acids produced a protein product
(79 kDa) that co-migrated with DN-JARID2 confirming that the size
of DN-JARID2 is ~80 kDa. This is also consistent with the mass
▸Figure 2. JARID2 LMW is a cleaved product of full-length JARID2 isoform-1.A A schematic showing three different isoforms of human JARID2, as predicted by ensembl annotations. The translation start site of each isoform is labelled using green
arrow. Predicted sizes (140, 120 and 106 kDa) of proteins corresponding to three isoforms have been indicated.
B CAGE-seq data showing the transcription start sites of JARID2 in different cell lines. CAGE peak is mainly observed at JARID2 isoform-1 in most cell types. JARID2 gene
structure is shown at the top.
C qPCR measurements of RNA levels (n = 3) for the three isoforms of JARID2 in HaCaT cells. The RNA levels are plotted relative to 18S rRNA. Level of JARID2 isoform-1 is
significantly higher than that of isoform-2 (***P < 0.001) and isoform-3 (****P < 0.0001). Data for three independent experiments are represented as mean  SE.
Multiple comparisons were performed and P-values were calculated using one-way ANOVA.
D Agarose gel showing RT–PCR products amplified using primers in exon 3 and exon 15 (2.9 kb) as well as RT–PCR product corresponding to JARID2 isoform-1 (3.7 kb)
amplified using the first (exon 1) and the last exon (exon 18). Only one product at the right size is observed indicating that it is unlikely that JARID2 might be a
product of an alternatively spliced isoform of JARID2.
E Ribosomal profiling data mapped on JARID2 isoform-1 and isoform-2. Main translation site corresponding to isoform-1 is highlighted using a dashed box.
F CRISPR-Cas9 knockout of JARID2 using a sgRNA guide designed to target main translation start site as seen in (E). Immunoblot revealed that ~80 kDa form was
removed from JARID2 KO lines. Densitometric measurements corresponding to the experiment are shown in Fig EV2D.
G Immunoblot after a full-length JARID2 isoform-1 was expressed from an exogenous vector in HaCaT cells showed an increase (2- to 3-fold) in ~80 kDa level.
Densitometric measurements are shown in Fig EV2E. An immunoblot with exogenous expression of 140kDa band in a control cell line is shown in Fig EV2F.
H Immunoprecipitation using anti-JARID2 antibody and followed by mass spectrometry identification of the ~80 kDa band detected JARID2 peptides spanning only C-
terminus of JARID2. The identified peptides are shown as red arrows on schematic of JARID2 sequence.
Source data are available online for this figure.
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spectrometry data where the N-terminal-most peptide is detected at
amino acid position 589 of JARID2 sequence (Fig EV3).
DN-JARID2 is required for cell differentiation
Previous studies have shown that PRC2 and JARID2 play an impor-
tant role in epidermal development and differentiation (Ezhkova
et al, 2009, 2011; Mejetta et al, 2011; Wurm et al, 2015). Therefore,
we explored the role of DN-JARID2 in epidermal differentiation.
First, we examined expression of DN-JARID2 in keratinocytes
(HaCaTs), which represent a good model for human epidermal dif-
ferentiation (Wilson, 2014). We differentiated HaCaTs by growing
them to confluency in low calcium medium for 4 weeks before
switching to high calcium medium for up to 6 days (Fig 3A). We
confirmed differentiation by measuring levels of epidermal differen-
tiation markers such as involucrin (IVL) and trans-glutaminase1
(TGase1) on days 0, 1, 3 and 6 after switching to high calcium
medium (Fig 3B). Interestingly, as differentiation progressed, DN-
JARID2 levels also increased up to 2-fold (Fig 3C). Therefore, we
speculated that DN-JARID2 might be important for HaCaT differenti-
ation.
To test this hypothesis, we compared differentiation in JARID2-
null HaCaTs and wild-type HaCaTs by comparing RNA levels of dif-
ferentiation markers keratin-1, keratin-10 and involucrin on day 0
and day 3 of differentiation (Fig 3D and E). We predicted that
removal of JARID2 should result in de-repression of differentiation
genes. However, in JARID2-null cells, we observed significant
down-regulation of involucrin and keratin-1 genes, which are earlier
reported to be polycomb targets in Keratinocytes (Sen et al, 2008)
(Fig 3D and E). Given that DN-JARID2 is the main form of JARID2
in keratinocytes and its level increases during differentiation, we
speculated that the impaired differentiation seen in JARID2-null
cells is due to removal of the DN-JARID2 form rather than the full-
length form of JARID2. In such a case, exogenous expression of DN-
JARID2 should be sufficient to rescue down-regulation of differentia-
tion markers. We therefore transfected JARID2-null cells with plas-
mids expressing the C-terminal ~80 kDa fragment (Appendix Fig
S1). Since we are yet to identify exact cleavage site of JARID2, this
C-terminal fragment should mimic the DN-JARID2 form. Signifi-
cantly, expression of the C-terminal ~80 kDa fragment was sufficient
to rescue the expression of differentiation markers, indicating that
the effect of JARID2 knockout on differentiation is most likely due
to DN-JARID2 (Fig 3D and E). As wild-type cells express low levels
of full-length JARID2, it could be argued that the impaired differenti-
ation in JARID2 KO might be a combined effect of both full-length
and DN-JARID2. To rule out this possibility, we also studied the
effect of exogenously expressed full-length JARID2 (FL-JARID2).
However, on day 3, expression of full-length JARID2 leads to
suppression of differentiation markers (Fig 3E). This supports a role
for DN-JARID2 in promoting differentiation, whereas full-length
JARID2, like other polycomb proteins, functions to suppress dif-
ferentiation.
DN-JARID2 is required for genome-wide up-regulation of
differentiation genes
To understand the effect of JARID2 knockout on genome-wide
expression patterns in HaCaTs, we carried out RNA-sequencing
analysis. Using RNA-seq data, we compared changes in gene expres-
sion patterns in JARID2-null vs JARID2-expressing wild-type HaCaT
cells. We identified 645 genes which changed expression by more
than 2-fold (P < 0.0001) between wild-type and JARID2-null cells
which included 269 up-regulated genes and 376 down-regulated
genes.
To further understand the functions of JARID2-regulated genes,
we investigated the biological pathways these genes are involved in
using Database for Annotation, Visualization and Integrated Discov-
ery (DAVID; Jiao et al, 2012). We observed that several genes
involved in DNA replication and G1/S transition of cell cycle were
up-regulated in JARID2 KO cells (Appendix Fig S2A). On the other
hand, several developmental and epidermal differentiation genes
were down-regulated as compared to wild-type cells (Appendix
Fig S2B).
This effect was much more pronounced when gene expression
was profiled after 3 days of differentiation in wild-type (WT) and
KO cells. After 3 days of differentiation, in wild-type HaCaTs,
epidermal differentiation genes were highly up-regulated and cell
cycle genes were down-regulated, further validating our differentia-
tion protocol (Appendix Fig S2C and D).
As compared to WT, in JARID2 KO cells epidermal differentiation
genes, as well as genes involved in extracellular matrix organisa-
tion, were significantly down-regulated indicating significant impair-
ment of differentiation in the absence of JARID2 (Fig 4A). In
addition, cell cycle genes in the KO cells were expressed at higher
levels indicating continued proliferation and inhibition of cell cycle
exit (Fig 4B). In summary, gene expression changes (Fig 4A and B)
upon JARID2 removal indicate that JARID2 is needed for up-regula-
tion of differentiation genes in keratinocytes.
We therefore first checked if the down-regulated genes are
indeed JARID2 targets. Analysis of genome-wide JARID2 Chromatin
Immunoprecipitation (ChIP) data (Kaneko et al, 2014a) from human
pluripotent cells showed enrichment for JARID2 binding in the
down-regulated genes compared to up-regulated genes (Fig 4C). We
also examined if these genes are targeted by polycomb proteins
(Margueron & Reinberg, 2011). Interestingly, down-regulated genes
have GC-rich promoters that are characteristic of polycomb target
genes (Appendix Fig S3A; Mendenhall et al, 2010). In addition, a
multi-gene plot of EZH2 enrichment at these genes showed that they
are bound by EZH2 in human ES cells as well as in keratinocytes
(Fig 4D) indicating that these genes are PRC2 targets. The gene
expression changes we observed in JARID2 KO can be due to altered
targeting of PRC2. In such a scenario, we expect up-regulated genes
to be the PRC2 targets. However, as compared to down-regulated
genes, up-regulated genes showed lower enrichment of JARID2 and
PRC2 (Fig 4C and D). Making it less likely that the down-regulation
of differentiation genes we observed in JARID2 KO is due to mere
rearrangement or altered targeting of PRC2. As JARID2 is required
for PRC2 recruitment (Landeira & Fisher, 2011; Holoch &
Margueron, 2017; Chen et al, 2018) and DN-JARID2 lacks PRC2
interacting domain, we investigated the possibility that down-regu-
lation of differentiation genes in keratinocytes lacking JARID2 might
be a consequence of changes in PRC2 activity. Our co-immunopreci-
pitation experiment confirmed that PRC2 subunit, EZH2, interacts
with full-length JARID2 but not with DN-JARID2 (Appendix Fig S3B
and C). However, similar to previous publications, we did not
observe any significant change in global H3K27me3 levels in
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Figure 3. Effect of JARID2 knockout on differentiation markers.
A The calcium-induced differentiation protocol used in this study. Up until day 0, cells were maintained in low calcium media and then induced to differentiate by
growing them in high calcium medium for 6 days. Cells were harvested for immunoblot at day 0, day 1, day 3 and day 6 of differentiation.
B Immunoblot showing increase in expression levels of differentiation markers involucrin (IVL) and Transglutaminase-1 (TGase-1) as differentiation progressed
indicating that keratinocyte differentiation protocol was successful. Protein levels on day 0 (D0), day 1 (D1), day 3 (D3) and day 6 (D6) of differentiation are shown.
C Immunoblot for JARID2 during D0, D1, D3 and D6 of differentiation (as in B) are shown.
D Effect of JARID2 removal on levels of differentiation markers involucrin (IVL), keratin-1 (KRT1) and keratin-10 (KRT10) mRNAs as measured in qPCR experiment relative
to 18S rRNA and the rescue using exogenous expression of DN-JARID2. The effect of exogenous expression of full-length JARID2 (FL-JARID2) in JARID2 knockout is also
shown. Data from wild-type HaCaTs, two independent JARID2 knockout (KO1 and KO2) HaCaT lines and KO cells exogenously expressing empty vector control, DN-
JARID2 and FL-JARID2 are shown. Data from three independent experiments (n = 3) are represented as mean  SE, and multiple comparisons were performed using
one-way ANOVA (****P < 0.0001, ***P < 0.001, **P < 0.01 and *P < 0.05).
E Levels of involucrin (IVL), keratin-1 (KRT1) and keratin-10 (KRT10) mRNAs as above but measured on day 3 of differentiation.
Source data are available online for this figure.
ª 2018 The Authors The EMBO Journal 38: e98449 | 2019 7 of 13
Diaa Al-Raawi et al Novel form of JARID2 in differentiation The EMBO Journal
0 3 6
Extracellular matrix disassembly
Hemidesmosome assembly
Collagen catabolic process
Epidermis development
Keratinocyte differentiation
Cell adhesion
Peptide cross-linking
-log(p-value)
0 4 8
Cell division
Mitotic nuclear division
Mitotic nuclear envelope …
Sister chromatid cohesion
Mitotic spindle organization
Cell proliferation
Mitochondrial …
-log(p-value)
A B
%
G
en
es
21
18
15
12
9
6
3
0
Loss of
H3K27me3
No change in
H3K27me3
Down-regulated
genes
Up-regulated
genes
H3K27me3
Ponceau S
D0     D3      D0   D3      D0    D3    D0    D3
WT KO1 KO2 ΔN-JARID2
JARID2 (Human) Human ES Human Keratinocytes
F
25
15
-2 20
20
10
-2 2
12
10
8
6
8
6
4
2
-2 20
C D
E
M
ea
n 
en
ric
hm
en
t o
f J
A
R
ID
2
Down
Up Up Up
Down Down
Distance to TSS (Kbs) Distance to TSS (Kbs)
H3
Distance to TSS (Kbs)
0M
ea
n 
en
ric
hm
en
t o
f E
ZH
2
Figure 4. Gene expression changes in JARID2-null cells.
A, B Functional enrichment of (A) 2-fold down-regulated and (B) 2-fold up-regulated genes in JARID2-null cells as compared to WT on day 3 of differentiation.
Functional categories are plotted on vertical axes and –log(p) values are plotted on horizontal axes.
C A metagene plot showing enrichment of full-length JARID2 in human-induced pluripotent cells at down-regulated genes (blue) as compared to up-regulated genes
(grey) in JARID2 KO cells. The plot is centred on Transcription Start Sites (TSS) of genes and distance from TSS is indicated on the x-axis.
D Metagene plots of average enrichment of EZH2 in ES cells and keratinocytes at down-regulated genes (blue) as compared to up-regulated genes (grey) in JARID2 KO
cells. The plots are centred on Transcription Start Sites (TSS) of genes and distance from TSS is indicated on the x-axes.
E Levels of H3K27me3 in WT, JARID2 KO lines and JARID2 KO lines expressing DN-JARID2. Histone H3 and Ponceau staining is used as a loading control. Densitometric
measurements corresponding to this experiment are shown in Fig EV4A.
F A bar-plot showing percentage of down- and up-regulated genes among genes which lose H3K27me3 vs which do not lose H3K27me3 modification during
differentiation.
Source data are available online for this figure.
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JARID2 KO or DN-JARID2 expressing cells (Figs 4E and EV4A).
Although this method cannot rule out the possibility of altered
targeting of PRC2, enrichment of PRC2 at down-regulated genes
rather than up-regulated genes in keratinocytes (Fig 4D) implies an
alternative scenario. In addition, we found that EZH2 levels in wild-
type HaCaTs and JARID2 KOs are very similar (Fig EV4B), ruling
out the possibility that the changes in gene expression pattern in
JARID2 KO cells are simply result of changes in EZH2 expression.
An alternative explanation is that DN-JARID2 is required for activa-
tion of differentiation genes. Our data (Fig 3D and E) support this
hypothesis. We also observed that those epidermal genes that lose
the H3K27me3 mark upon differentiation (Sen et al, 2008) are
highly enriched in down-regulated genes. 4.2% of down-regulated
genes lose H3K27me3 upon day 3 of differentiation as compared to
only 1.6% of up-regulated genes and 1.4% of all genes (Fig 4F).
This suggests that JARID2 is mainly required for activation of genes
that lose their H3K27me3 mark.
Since DN-JARID2 contains conserved domains that are typical
of the jumonji family of demethylases, we explored a possibility
that at these genes DN-JARID2 helps in removal of the H3K27me3
mark. In such a scenario, inhibition of EZH2 enzymatic activity
should have the opposite effect to that of JARID2 knockout and we
should see up-regulation of differentiation genes. We therefore
treated wild-type cells expressing JARID2 with EZH2 inhibitor
UNC1999. Following 24-h treatment with UNC1999, H3K27me3
was reduced to very low level (Fig EV4C). However, this did not
result in activation of epidermal differentiation genes (Fig EV4D).
This is in agreement with a previous publication, which showed
that, in keratinocytes, removing EZH2-mediated repression is not
enough and additional factors are required for activation of poly-
comb targeted epidermal genes (Wurm et al, 2015). Another possi-
bility is that DN-JARID2 is required for activation of transcription
by aiding recruitment of certain transcription factors (Wurm et al,
2015) or RNA pol II (Landeira et al, 2010) or both. Indeed, an
analysis of promoter sequences of down-regulated genes showed
significant enrichment of motif of AP-1 transcription factor FOSL
(Fig EV4E), which is needed for activation of epidermal differentia-
tion genes (Wurm et al, 2015). Moreover, we did not observe
enrichment of AP-1 motif in up-regulated genes indicating that
down-regulated genes are targets of AP-1. This suggested that DN-
JARID2 might aid AP-1-mediated up-regulation of differentiation
genes. Interestingly, previous publication shows that interplay
between EZH2 and AP-1 transcription factors is needed for kerati-
nocyte differentiation (Wurm et al, 2015). EZH2-mediated methyla-
tion of AP-1 factor FOSL-2 inhibits its activity, which is relieved
upon differentiation. However, we could not detect a direct interac-
tion of either form of JARID2 with AP-1 (Appendix Fig S4A and B)
suggesting that DN-JARID2 might not directly interact but might
indirectly aid in activity of AP-1 transcription factors by relieving
their EZH2-mediated repression.
Discussion
It is well established that the N-terminal domain of JARID2 is
needed for its interaction with EZH2 and its recruitment to chro-
matin (Son et al, 2013; Kaneko et al, 2014a; Sanulli et al, 2015;
Cooper et al, 2016; Chen et al, 2018). By contrast, the C-terminal of
JARID2 has not been studied in detail. One of the reasons for this is
that it has been shown to be unnecessary for EZH2 enzymatic activ-
ity or binding (Son et al, 2013; Kaneko et al, 2014a; Cooper et al,
2016). This is despite the fact that C-terminal contains several
conserved domains typical of the jumonji family, as well as the zinc
finger and ARID domains that are involved in DNA binding (Li et al,
2010).
In this study, we discovered that JARID2 exists as an ~80 kDa
low molecular weight form that consists of the C-terminal domain.
This low molecular weight form (which we termed DN-JARID2) is a
cleavage product of full-length JARID2 that lacks PRC2-interacting
domains and is the predominant form in many lineage-committed
human cells including keratinocytes. This is a significant finding as
the presence of another form of JARID2 can provide answers to
multiple unsolved questions related to JARID2’s association with
polycomb function.
In keratinocytes, we could mainly detect C-terminal portion (or
DN-JARID2) of JARID2, but its N-cleaved portion was missing. This
suggests that N-terminal portion is not very stable in these cells.
This can explain the discrepancy in JARID2 mRNA level and DN-
JARID2 protein levels in lineage-committed cells. In these cells,
JARID2 mRNA is expressed at detectable but albeit low levels, while
DN-JARID2 protein levels are much higher. It can be hypothesised
that the cleavage of unstable N-terminal portion from full-length
JARID2 can make its C-terminus more stable leading to higher levels
of DN-JARID2 than expected from JARID2 mRNA levels.
We find that during keratinocyte differentiation DN-JARID2
levels increase. This can explain the reported decrease in JARID2
full-length levels during differentiation (Zhang et al, 2011; Sanulli
et al, 2015), which is likely due to increased cleavage of isoform-1
in addition to a decrease in RNA levels (Shen et al, 2009). We
show that in human keratinocytes, JARID2 removal leads to
suppression of PRC2 targets such as differentiation genes.
Although consistent with previous observations (Shen et al, 2009;
Landeira et al, 2010), this is puzzling, as it is expected that
JARID2 knockout should interfere with PRC2 targeting and hence
lead to de-repression of its target genes as observed in case of
removal of other PRC2 components (Azuara et al, 2006; Boyer
et al, 2006; Pasini et al, 2007; Shen et al, 2008). We show that
decreased expression of epidermal differentiation genes seen in
JARID2-null cells can be reversed by expression of the C-terminal
fragment similar to DN-JARID2. This raises the exciting possibility
that DN-JARID2 is needed for activation of differentiation genes.
Enrichment of AP1 transcription binding motifs at JARID2 regu-
lated genes suggests that DN-JARID2, directly or indirectly, might
aid in recruiting transcriptional activators such as AP-1 at these
genes. This is consistent with the previous observation, which
shows that JARID2 is required for RNA pol II recruitment during
differentiation (Landeira et al, 2010).
This is important as identification of DN-JARID2 and its role in
activation of differentiation genes implies that JARID2 might func-
tion in two ways. In its full-length form it acts as a transcriptional
co-repressor that functions through its interaction with PRC2
whereas in its cleaved form it acts as an activator for PRC2 target
genes. We speculate that this might be a general regulatory mecha-
nism of PRC2 components, as distinct molecular weight forms have
been also reported in the case of AEBP2 (Kim et al, 2015), another
subunit of JARID2 containing PRC2 complex. The presence of
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another form of JARID2 can also provide additional insight into how
polycomb target genes are activated during differentiation.
It is known that PRC2 preferentially binds to GC-rich regions.
However, it is not clear why PRC2 does not target CpG-rich promot-
ers at active genes. Given that the C-terminal of JARID2 also has a
preference for GC-rich sites (Mendenhall et al, 2010), it is possible
that DN-JARID2 form might bind to CpG-islands at active genes and
protect them from PRC2-mediated repression (Jermann et al, 2014;
Riising et al, 2014). Recently, it was shown that EZH2 binds to RNA
and nucleosomes in a mutually exclusive manner (Beltran et al,
2016). However, it is not clear what triggers EZH2’s release from
chromatin. It can be imagined that cleavage of JARID2 might lead to
release of EZH2 from chromatin. But how JARID2 is cleaved? Is not
entirely clear and needs to be studied further. However, strong
enrichment of AP-1 motif in the promoters of down-regulated genes
in JARID2-null cells suggests that directly or indirectly DN-JARID2
plays a role in AP-1-mediated gene regulation. Therefore, we
propose a model (Fig 5) where, upon differentiation, JARID2 is
cleaved leading to removal of PRC2 and probably H3K27me3 at
subset of genes. The resulting DN-JARID2 form, directly or indi-
rectly, aids in recruitment of transcriptional activators such as AP-1
resulting in up-regulation of differentiation genes. However, the
relation between AP-1 transcription factors and DN-JARID2 will
need further investigation.
Materials and Methods
Cell culture
A spontaneously immortalised human keratinocytes cell line HaCaT
and human embryonic kidney cells HEK-293T were grown in
Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplement
with 5% foetal bovine serum (FBS) and 1% penicillin-streptomycin
(10,000 U/ml) in 5% humidified CO2 incubator at 37°C. To main-
tain HaCaT cells in undifferentiated phenotype as previously
described (Wilson, 2014), HaCaT cells were cultured in DMEM with
10% Ca2+-chelated FBS, 200 mM L-Glutamine and 0.03 mM
calcium at 75% confluence. For keratinocyte differentiation, HaCaT
cells were grown at full confluency in high calcium (2.8 mM)
growth medium for the indicated time points.
Transfections
JARID2 siRNAs targeting exon 3 and exon 15 were obtained from
Sigma. 2 × 105 HaCaT cells were transiently transfected with
80 pmol siRNAs using Lipofectamine RNAiMAX (Invitrogen) for
48 h. Non-silencing control (NSC) was used as control. HEK-293T
were transiently transfected as 3:1 ratio of reagent to DNA using X-
tremeGENE9 DNA transfection reagent (Roche). Full-length JARID2
was cloned in pEF6 vector with N-terminal flag-tag, and shorter
fragments of JARID2 (Appendix Fig S1A) were cloned in pcDNA3.1
vector. Stable HaCaT cells were generated by transfecting cells with
5 lg JARID2 expression constructs using Amxa Nucleofector kit V
(Lonza) for 24 h. After 24 h, medium was refreshed. Stable cells
were selected by growing them in DMEM medium containing
10 lg/ml of Blasticidin or 500 lg/ml Geneticin antibiotics. The
expression of the construct was tested by immunoblotting.
CRISPR/Cas9-mediated genome editing
sgRNA targeting JARID2 was designed using Wellcome Trust Sanger
Institute Genome Editing database (WGE) (Hodgkins et al, 2015).
sgRNA was selected with minimum off-target effects and close to
translational start site (ATG) of isoform-1. HaCaT cells were electro-
porated with 5 lg pX459 vector (Addgene) containing sgRNA target-
ing JARID2 using Amaxa Cell Line Nucleofector kit V (Lonza) for
24 h. Transfected cells were selected for 3 days in a medium
containing 0.5 lg/ml puromycin. After that cells were then main-
tained in DMEM for 5 days. Selected cells were serially diluted to
single cells and were let to grow till colonies were grown. Homozy-
gous mutations were confirmed by amplifying targeted loci using
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Figure 5. A model predicting the role of DN-JARID2 in differentiation.
Jarid2 is present as a full-length protein in multi-potent and undifferentiated
cells. Full-length JARID2 with the help of N-terminal PRC2 interacting domain
can recruit PRC2 and suppress differentiation genes. Upon differentiation N-
terminal of JARID2 is cleaved (DN-JARID2) which leads to reduction in PRC2
recruitment and possibly H3K27me3 levels at differentiation genes. However,
PRC2 removal is not sufficient for activation of differentiation genes and, in
addition, DN-JARID2 is required for their up-regulation likely through, directly or
indirectly, facilitating transcription factors such as AP-1.
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RT–PCR. RT–PCR products were cloned into pJET1.2 blunt vector
(ThermoFisher Scientific), and at least 10 bacterial colonies were
picked up for genotyping.
Immunoblotting
Cells were lysed with 20 mM Tris pH 7.5, 150 mM NaCl, 0.5%
Deoxycholic acid, 10mM EDTA and 0.5% Triton X-100 containing
protease inhibitor cocktail (complete ULTRA tablets, Roche).
Histones were extracted from cells by acid extraction method
(Halsall et al, 2015). According to standard procedure, lysates were
treated with loading buffer, separated by 12–10% SDS–PAGE, trans-
ferred onto nitrocellulose membrane (Bio-Rad) using Trans-Blot
Turbo Transfer System (Bio-Rad) and immunoblotted with follow-
ing primary antibodies: JARID2 (1:1,000, Cell Signaling Technology,
USA; 1:1,000, GTX129020, GeneTex), EZH2 (1:1,000, Cell Signaling
Technology, USA), involucrin (1:1,000, Sigma), transglutaminase-1
TGase-1 (1:1,000, Santa Cruz Biotechnology, INC), c-Jun (1:1,000,
Cell Signaling Technology, USA) and H3K27me3 (1:1,000, 07-449
Millipore). GAPDH (1:1,000, ThermoFisher Scientific) and C-
terminus of histone H3 (1:5,000, Abcam) are used as loading
controls. Immunoblots were visualised using fluorescence detection
and scanned using odyssey infrared detection system (LI-COR Bio-
sciences). Densitometry analysis was done using Image Studio Lite
(LI-COR Biosciences).
Immunofluorescence
Cells were cultured on cover slips and were fixed in PBS containing
4% (w/v) paraformaldehyde for 10 min at RT. The fixed cells were
permeabilised with 0.2% Triton X-100 in PBS for 3 min and then
blocked with 5% BSA for 1 h. Cells were incubated with 6X His
antibody overnight (1:500, Thermofisher) at 4°C, washed three
times using PBS and incubated with Fluorescein (FITC)-AffiniPure
donkey anti-Mouse IgG secondary antibody (Jackson Immuno-
Research Laboratories Inc) for 1 h. Coverslips were washed thor-
oughly, mounted using Vectorshield with DAPI and analysed using
a Nikon A1R confocal microscope.
RNA-sequencing and metagene analyses
RNA-sequencing was carried out on RNA extracted from wild-type
HaCaT cells and JARID2-null HaCaT cells at day 0 and day 3 of dif-
ferentiation. The sequencing was carried out on three biological trip-
licates. RNA-sequencing libraries were prepared using TrueSeq
method. All the libraries were paired-end sequenced on an Illumina
HiSeq 2500 machine (University of Birmingham). Sequences were
quality filtered and trimmed using cutadapt. The reads were mapped
using Tophat package (Trapnell et al, 2009) against human genome
(hg19). Differential analysis was done using cuffdiff programme.
Differential genes were identified using false discovery cut-off of
1 × 105 and used for further analysis. Analysis of functional anno-
tation was carried out using DAVID (Jiao et al, 2012). Metagene
plots and heatmap were generated using DeepTools package
(Ramirez et al, 2014). De novo motif finding was carried out using
Homer software (Heinz et al, 2010). Analysis of H3K27me3-positive
genes in HaCaTs was carried out using previously published data
(Sen et al, 2008).
Co-Immunoprecipitation
HEK-293T cells were transfected with Empty vector (Control), Flag-
tagged full-length JARID2 and DN-JARID2 vectors. After 72 h of
transfection, protein was extracted from all sample. For each IP,
protein G-coated magnetic Dynabeads were suspended and incu-
bated with desired antibody (1–10 lg). After 10-min incubation with
antibody, beads were washed and Dynabeads-Antibody complex
was incubated with protein samples. After washing the beads,
proteins were eluted in elution buffer and SDS sample buffer and
loaded on standard SDS–PAGE gel along with 5% whole-cell extract.
The presence of co-immunoprecipitated proteins was verified using
immunoblotting with respective antibodies.
Mass Spectrophotometric protein Identification
The immunoprecipitation of JARID2 was carried out using mono-
clonal anti-JARID2 antibody (Cell Signalling Technology, USA) as
mentioned in co-immunoprecipitation protocol. The eluted protein
sample was separated using an SDS–PAGE and silver stained.
80 kDa band was cut and peptides were identified using the Q-Exac-
tive HF mass spectrophotometer.
Statistical analysis
Result analysis was performed using GraphPad Prism version 6 soft-
ware. Data were represented as mean  SE of three independent
experiments. Student’s t-test was used to compare two groups.
Multiple comparisons were done using one-way ANOVA. A P-value
of < 0.05 was considered significant.
Data availability
The raw and processed RNA-seq data are deposited in GEO database
(accession no. GSE102116; https://www.ncbi.nlm.nih.gov/geo/que
ry/acc.cgi?acc=GSE102116). EZH2 metagene plots and H3K27me3
heatmap were generated using ES and Keratinocyte data deposited
in ENCODE database (GEO accession no.: GSE29611; https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29611). JARID2 meta-
gene plots were created using previously published dataset (GEO
accession no: GSM1180131; https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSM1180131).
Expanded View for this article is available online.
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